Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?

Journal of Investigative Dermatology

Volumn 137, Issue 8, 2017, Pages 1612-1613

  Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; PSORIASIS; RISK REDUCTION; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASES; GLOBAL HEALTH; INCIDENCE; PROCEDURES; TRENDS;

BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASES; COMORBIDITY; GLOBAL HEALTH; HUMANS; INCIDENCE; PSORIASIS;

EID: 85024899279     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2017.06.001     Document Type: Note

References (10)

1. Bissonnette, R., Harel, F., Krueger, J.G., Guertin, M.-C., Chabot-Blanchet, M., Gonzalez, J., et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol 137 (2017), 1638–1645.
2. Bissonnette, R., Tardif, J.C., Harel, F., Pressacco, J., Bolduc, C., Guertin, M.C., Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging 6 (2013), 83–90.
3. Dowlatshahi, E.A., Kavousi, M., Nijsten, T., Ikram, M.A., Hofman, A., Franco, O.H., Wakkee, M., Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol 133 (2013), 2347–2354.
4. Egeberg, A., Thyssen, J.P., Jensen, P., Gislason, G.H., Skov, L., Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. [e-pub ahead of print] Acta Derm Venereol, 2017, 10.2340/00015555-2657 (accessed 24 June 2017).
5. Gisondi, P., Girolomoni, G., Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 35 (2009), 313–324.
6. Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006), 1735–1741.
7. Kaye, J.A., Li, L., Jick, S.S., Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008), 895–902.
8. Shapiro, J., Cohen, A.D., David, M., Hodak, E., Chodik, G., Viner, A., Kremer, E., Heymann, A., The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007), 629–634.
9. Török, L., Tóth, E., Bruncsák, A., Untersuchungen uber die beziehungen zwischen psoriasis und kardio-vaskularen erkrankungen. Z Hautkr 57 (1982), 734–739.
10. Wu, J.J., Poon, K.Y., Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. J Drugs Dermatol 13 (2014), 932–934.